Gilead Sciences has announced its intention to acquire an immunology-focused biotech firm, a move that is poised to significantly impact the operational landscape for Galapagos.
This acquisition is expected to enhance Gilead's capabilities in immunology, potentially increasing throughput and capacity in drug development.
For Galapagos, this acquisition may serve as a lifeline, offering new opportunities for collaboration and resource sharing in the competitive biopharmaceutical market.